Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Lymphoma 4Lymphoma, Follicular 3Neoplasms 2Prostatic Neoplasms 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms, Nerve Tissue 1Neoplasms, Germ Cell and Embryonal 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Leukemia 1Glioma 1Glioblastoma 1

Interventions

Cyclophosphamide 53Etoposide 33Temozolomide 28Irinotecan 28Melphalan 25Filgrastim 25Topotecan 24Carboplatin 243-Iodobenzylguanidine 23Isotretinoin 20Granulocyte Colony-Stimulating Factor 17sargramostim 16humanized 3F8 anti-GD2 monoclonal antibody 16dinutuximab 16Granulocyte-Macrophage Colony-Stimulating Factor 16fludarabine 15Vincristine 15Doxorubicin 15Cisplatin 15Peripheral Blood Stem Cell Transplantation 14Interleukin-2 14Busulfan 13naxitamab 12Thiotepa 12Radiotherapy 12aldesleukin 11fludarabine phosphate 10etoposide phosphate 8Mesna 8Ifosfamide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neuroblastoma × keyhole-limpet hemocyanin × Clear all
NCT02745756 2017-08-30

A Combined Cell Therapy Approach to the Treatment of Neuroblastoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Withdrawn
CNS

Neoplasms, Neoplasms, Nerve Tissue, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡